Biomarker & Intervention Discovery
Schizophrenia
Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.
US DALYs867.6KWHO GHE 2021 · all ages
Global DALYs15.04MWHO GHE 2021 · worldwide
US mortality704 deaths/yrWHO GHE 2021
Global mortality7,491 deaths/yrWHO GHE 2021 · worldwide
NIH funding$262MFY2025 · RCDC estimate
Funding levelModerate
Spontaneous remissionSpontaneous full remission rare (<10%); after first episode, ~80% relapse within 5 years without maintenance…
Best-intervention remissionLong-acting injectable antipsychotics (LAIs): 30-50% reduction in relapse vs oral antipsychotics (PALIPERIDONE…
Gap sizeLarge — LAIs chronically underused; clozapine for TRS grossly underused; early intervention services reach only a…
Primary barrierpractice
Full remission profile →
Remission & chronicity
Spontaneous remission
Spontaneous full remission rare (<10%); after first episode, ~80% relapse within 5 years without maintenance antipsychotic; functional disability accumulates over time; 20% achieve good long-term outcome
Best-intervention remission
Long-acting injectable antipsychotics (LAIs): 30-50% reduction in relapse vs oral antipsychotics (PALIPERIDONE PALMITATE, aripiprazole monthly); clozapine for treatment-resistant: 30-60% response in patients who failed 2 other antipsychotics; critical period intensive early intervention (NAVIGATE program): 3x better employment, 30% less symptom burden at 2 years
Gap size
Large — LAIs chronically underused; clozapine for TRS grossly underused; early intervention services reach only a fraction of FEP patients
Clozapine is used in only 4% of TRS patients in the US despite clear efficacy (should be ~30%); LAIs offered to only 15-25% of patients despite superior relapse prevention vs oral; stigma and structural barriers delay first treatment by 1-2 years on average; many patients never receive coordinated specialty care
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC.
Agents ranked: ● Clinical >
● Mechanistic >
● Correlative.
Pipeline results not yet available. Run: python -m biomarker_pipeline.run_for_diseases --skip-llm
Clinical Trials
Recruiting and recently completed trials from ClinicalTrials.gov.
Data retrieved 2026-07-06.
No recent clinical trials found on ClinicalTrials.gov for this condition.
Agents Found By Disease-Level Search
Searched directly from “Schizophrenia” via ClinicalTrials.gov interventions and Open Targets'
disease→drug data — independent of the 0-gene target panel above.
This surfaces agents whose mechanism doesn't route through a curated gene (combination
therapies, standard-of-care drugs, targets outside the panel).
Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."